Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Minute Insight: QuantumDX Launches Panel Test For Flu, COVID-19 And RSV

Executive Summary

Medtech Insight spoke to the company’s CEO to find out what the announcement means for QPOC users, and how truly rapid point-of-care testing will aide triage.

You may also be interested in...



QuantumDX Inks Deal To Distribute IVD Tests In China

The CEO of QuantumDX, Jonathan O’Halloran, spoke to Medtech Insight about the benefits of selling diagnostics in China and argued for a pragmatic approach to IP protection when launching in a country where counterfeiting is common.

MDR And IVDR – Similar Step Ups, Varying Commercial Impacts

Medtech Insight spoke to the CEOs of two companies that recently had very different experiences with the new European IVDR and MDR regulations to gauge their thoughts on any potential commercial impacts.

How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies

UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145458

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel